Unlocking the Potential of Multigene Parallel Sequencing: A Concomitant Germline RET and BRCA1 Mutation in a Hereditary Medullary Thyroid Carcinoma
Article Sidebar
Main Article Content
Abstract
We report a rare case of a 33-year-old South Asian woman who visited the Molecular Pathology and Genomics Department referred for hereditary germline cancer genetic testing after being diagnosed with high-grade, multifocal medullary carcinoma of the thyroid. Genetic counselling showed an elaborate family history of cancer. Germline cancer testing on 113 genes for pancancer panel by next-generation sequencing showed a pathogenic heterozygous single nucleotide variant in RET gene c.1901G>C p.Cys634Ser (codon10) and an incidental finding of the presence of a pathogenic splice variant in BRCA1 gene c.213-1G>C at the intron 4 of the gene. The patient was further managed with a paradigm of Precision Medicine (PM) based on the 5Ps like participation, psychological support, and prediction of risk assessment, prevention, and personalisation.
Article Details
Copyright (c) 2024 Kaler AK, et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell. 1985;42(3):581-588. Available from: https://doi.org/10.1016/0092-8674(85)90115-1
Goodfellow PJ, Wells SA Jr. RET gene and its implications for cancer. J Natl Cancer Inst. 1995;87(20):1515-1523. Available from: https://doi.org/10.1093/jnci/87.20.1515
Zhao L, Wang N, Zhang D, Jia Y, Kong F. A comprehensive overview of the relationship between RET gene and tumor occurrence. Front Oncol. 2023;13:1090757. Available from: https://doi.org/10.3389/fonc.2023.1090757
Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl). Available from: https://doi.org/10.1177/1758834011422556
Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: Normal and abnormal functions. Endocrinology. 2004;145(12):5448-5451. Available from: https://doi.org/10.1210/en.2004-0922
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc. 1996;276(19):1575-1579. Available from: https://pubmed.ncbi.nlm.nih.gov/8918855/
Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis. J Med Genet. 2000;37(11):817-827. Available from: https://doi.org/10.1136/jmg.37.11.817
Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6(1):70-74. Available from: https://doi.org/10.1038/ng0194-70
Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6(1):70-74. Available from: https://doi.org/10.1038/ng0194-70
Quadro L. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab. 1994;79(2):590-594. Available from: https://doi.org/10.1210/jcem.79.2.7913936
Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):475-485. Available from:https://doi.org/10.1016/j.clon.2010.05.002 .
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. GeneReviews® [Internet]. 1998 Sep 4 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. Seattle (WA): University of Washington; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/
Illumina. Illumina DNA Prep with Enrichment, Reference Guide. August 2021. Available from: https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/illumina_prep/illumina-dna-prep-with-enrichment-reference-guide-1000000048041-07.pdf
Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B. Exon 5 of the RET proto-oncogene: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest. 2005;28(10):905-909. Available from: https://doi.org/10.1007/bf03345322
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc. 1996;276(19):1575-1579. Available from: https://pubmed.ncbi.nlm.nih.gov/8918855/
Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res. 2013;752(1):36-44. Available from: https://doi.org/10.1016/j.mrrev.2012.09.002
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc. 1996;276(19):1575-1579. Available from: https://pubmed.ncbi.nlm.nih.gov/8918855/
Punales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: Variable clinical features and clinical outcome. J Clin Endocrinol Metab. 2003;88(6):2644-2649. Available from: https://doi.org/10.1210/jc.2002-021422
Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A, Robledo M, Biarnes J, Barontini M, Links TP, et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocr Relat Cancer. 2008;15(4):1035-1041. Available from: https://doi.org/10.1677/erc-08-0105
Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res Rev Mutat Res. 2013;752(1):36-44. Available from: https://doi.org/10.1016/j.mrrev.2012.09.002
Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612. Available from: https://doi.org/10.1089/thy.2008.0403
Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997;103(1):60-69. Available from: https://doi.org/10.1016/s0002-9343(97)00024-7
Li SY, Ding YQ, Si YL, Ye MJ, Xu CM, Qi XP. 5P strategies for management of multiple endocrine Neoplasia Type 2: A paradigm of precision medicine. Front Endocrinol (Lausanne). 2020;11:543246. Available from: https://doi.org/10.3389/fendo.2020.543246
Kumar S, Sharma G, George M, Joseph L. Vandetanib: A new drug for metastatic medullary thyroid cancer. Int J Pharma Prof Res. 2011;2(3):351-353. Available from: https://www.ijppronline.com/index.php/IJPPR/article/view/79
US Food and Drug Administration. FDA approves Cometriq to treat rare type of thyroid cancer. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: https://ir.exelixis.com/news-releases/news-release-details/fda-approves-cometriqtm-cabozantinib-treatment-progressive
Bradford D, Larkins EL, Mushti SL, Rodriguez L, Skinner AM, Helms WS, et al. FDA approval summary: Selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021;27(8):2130-2135. Available from: https://doi.org/10.1158/1078-0432.ccr-20-3558